Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | IDE | P14735 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | HLCS | P50747 | 6/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL28084581 | 0.93 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL9280317 | 0.93 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL27482647 | 0.92 | TDP1 (0.74) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8011736 | 0.91 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8011738 | 0.91 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL3790437 | 0.91 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL693036 | 0.91 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL28248497 | 0.89 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL1033634 | 0.89 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8188769 | 0.88 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050329-A1 | METHODS FOR COSMETIC SKIN REMODELING | ELC MAN LLC (US) | 2024-02-15 | — | — | US | claimed |
| CN-111333664-A | Biotin cross-linking agent, application and preparation method thereof | 苏州昊帆生物股份有限公司 | 2020-06-26 | — | — | CN | claimed |
| WO-2002070702-A2 | POLYPEPTIDES CAPABLE OF INTERACTING WITH SMAD POLYPEPTIDE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-09-12 | — | — | WO | claimed |
| EP-1212414-A2 | POLYPEPTIDES CAPABLE OF INTERACTING WITH THE SMAD PEPTIDE AND COMPRISING THE SEQUENCE PP(T/N)K | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-06-12 | — | — | EP | claimed |
| WO-2001014413-A2 | POLYPEPTIDES CAPABLE OF INTERACTING WITH THE SMAD PEPTIDE AND COMPRISING THE SEQUENCE PP (T/N)K | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2001-03-01 | — | — | WO | claimed |
| EP-0222889-B1 | CYTIDINE ANALOGS | AMOCO CORP (US) | 1993-10-27 | — | — | EP | claimed |
| EP-0222889-A4 | CYTIDINE ANALOGS. | INTEGRATED GENETICS INC (US) | 1988-09-28 | — | — | EP | claimed |
| EP-0222889-A1 | CYTIDINE ANALOGS. | INTEGRATED GENETICS INC (US) | 1987-05-27 | — | — | EP | claimed |
| WO-1986006726-A1 | CYTIDINE ANALOGS | INTEGRATED GENETICS, INC. (US) | 1986-11-20 | — | — | WO | claimed |
| CN-119546632-A | Cross-linked type V collagen assay | 北欧生物科技公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-118451106-A | Combination therapy of Claudin 18.2 antagonists and PD-1/PD-L1 axis inhibitors | 苏州创胜医药集团有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-114630840-B | Novel anti-CLDN 18.2 antibodies | 苏州创胜医药集团有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240050329-A1 | METHODS FOR COSMETIC SKIN REMODELING | ELC MAN LLC (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4041185-A1 | METHODS FOR COSMETIC SKIN REMODELING | ELC Management LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-5405950-A | N4 -substituted cytidines and process for incorporation into an oligonucleotides | AMOCO CORPORATION (US) | 1995-04-11 | — | — | US | disclosed |
| EP-0222889-B1 | CYTIDINE ANALOGS | AMOCO CORP (US) | 1993-10-27 | — | — | EP | disclosed |
| US-5108893-A | Oxidase, while produces peroxides an superoxide anions, reacting with substrate, chemiluminescent reagent and enhancer emitted light | CANBERRA INDUSTRIES, INC. (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0222889-A4 | CYTIDINE ANALOGS. | INTEGRATED GENETICS INC (US) | 1988-09-28 | — | — | EP | disclosed |
| EP-0222889-A1 | CYTIDINE ANALOGS. | INTEGRATED GENETICS INC (US) | 1987-05-27 | — | — | EP | disclosed |
| WO-1986006726-A1 | CYTIDINE ANALOGS | INTEGRATED GENETICS, INC. (US) | 1986-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050329-A1 | METHODS FOR COSMETIC SKIN REMODELING | CUTA, PLOD3, KRT18 | TDP1 612/4885MEN1 2593/4885ABL1 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.